HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

When the ISS comes down, will its drug R&D be lost in space?

As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.

By PharmaVoice · Jun 3, 2026 · via PharmaVoice
When the ISS comes down, will its drug R&D be lost in space?

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
The WeekFiercePharma ↗
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs…
Jun 4, 2026
Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
The WeekFierceBiotech ↗
Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
Alnylam has partnered with the person who helped put the "T" in ChatGPT, paying $30 million to work with Jakob…
Jun 4, 2026
Revolution Medicines’ Pancreatic Cancer Drug Draws Early Expansion Buzz
The WeekBriefing
Revolution Medicines’ Pancreatic Cancer Drug Draws Early Expansion Buzz
Even before approval, Revolution Medicines’ pancreatic cancer asset is prompting discussion of how and when it…
Jun 4, 2026